Iterum Therapeutics plc (ITRMF) Liabilities and Shareholders Equity (2017 - 2025)

Iterum Therapeutics has reported Liabilities and Shareholders Equity for 9 years, with the latest figure at $32.5 million in Q3 2025.

• On a quarterly basis, Liabilities and Shareholders Equity rose 104.11% year-over-year to $32.5 million in Q3 2025; TTM through Sep 2025 was $144.1 million, a 89.63% increase from a year earlier, with the FY2024 full-year figure at $44.6 million, up 69.83% from the prior year.
• Liabilities and Shareholders Equity was $32.5 million for Q3 2025 at Iterum Therapeutics, down from $34.0 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $115.2 million in Q1 2021, with the low at $14.2 million in Q2 2024.
• Average Liabilities and Shareholders Equity over 5 years is $56.8 million, with a median of $51.0 million recorded in 2023.
• The sharpest annual moves came in 2021 and 2024: Liabilities and Shareholders Equity soared 274.66% in 2021, then slumped 72.22% in 2024.
• Over 5 years, Liabilities and Shareholders Equity stood at $91.5 million in 2021, then decreased by 26.97% to $66.8 million in 2022, then slumped by 60.71% to $26.3 million in 2023, then soared by 69.83% to $44.6 million in 2024, then declined by 27.12% to $32.5 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $32.5 million (Q3 2025), $34.0 million (Q2 2025), and $33.0 million (Q1 2025), per Business Quant data.